NewsDialy
A stock exchange listing is not automatic once granted.
Exchanges require companies to keep meeting minimum financial and trading standards on an ongoing basis; fall below those thresholds, and the exchange opens a formal compliance review that can end in delisting.
(Nasdaq: DYAI), the Jupiter, Florida biotech operating as Dyadic Applied BioSolutions, announced July 24, 2026, that Nasdaq confirmed the company has regained compliance with Listing Rules 5550(a)(2) and 5550(b), ending that review.
What the 8-K actually confirms The filing, categorized under "Other Events," makes one concrete statement: Nasdaq has certified Dyadic's return to compliance, and DYAI shares remain listed and tradeable on The Nasdaq Capital Market.
Keep reading